ScreenerHero

RVTY Revvity, Inc. Common Stock

NYSE · US · Healthcare · Diagnostics & Research · revvity.com
151.50USD-0.02%Mkt Cap: 16.91B $P/E: 72.50

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and servi…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc Common Stock
$242.11BUSDP/E 35.5
DHR
Danaher Corporation Common Stock
$150.48BUSDP/E 38.2
NTRA
Natera, Inc. - Common Stock
$59.15BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc. Common Stock
$47.30BUSDP/E 33.1
IQV
IQVIA Holdings, Inc. Common Stock
$42.50BUSDP/E 32.2
WAT
Waters Corporation Common Stock
$41.75BUSDP/E 107.4
ILMN
Illumina, Inc. - Common Stock
$41.23BUSDP/E 50.8
IDXX
IDEXX Laboratories, Inc. - Common Stock
$40.89BUSDP/E 36.4
MTD
Mettler-Toledo International, Inc. Common Stock
$29.78BUSDP/E 34.0
DGX
Quest Diagnostics Incorporated Common Stock
$25.75BUSDP/E 25.0
LH
Labcorp Holdings Inc. Common Stock
$25.02BUSDP/E 25.5
GH
Guardant Health, Inc. - Common Stock
$23.86BUSD
MEDP
Medpace Holdings, Inc. - Common Stock
$16.73BUSDP/E 35.2
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
CRL
Charles River Laboratories International, Inc. Common Stock
$13.85BUSD
ICLR
ICON plc - Ordinary Shares
$12.50BUSDP/E 249.3
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V. Common Shares
$9.24BUSDP/E 22.7
GRAL
GRAIL, Inc. - Common Stock
$6.40BUSD

Key Statistics

Company
Market Cap16.91B USD
Enterprise Value19.23B USD
Revenue (TTM)2.91B USD
Gross Profit1.56B USD
Net Income (TTM)241.20M USD
Revenue/Share25.77 USD
Last Price151.50 USD
Fiscal Year EndDec 2025
MR QuarterJul 2026
Employees11.0K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)72.50
P/E (Forward)25.72
PEG0.73
EV/EBITDA21.95
EV/Revenue6.60
P/S5.81
P/B2.34
EPS (TTM)2.09
EPS (Forward)5.89
52W Range
81.2291% of range158.28
52W High158.28 USD
52W Low81.22 USD
Profitability
Gross Margin54.77%
Oper. Margin17.05%
EBITDA Margin30.08%
Profit Margin8.45%
ROE3.33%
ROA1.98%
Growth
Revenue Growth1.30%
Earnings Growth1.20%
Cash Flow & Leverage
Operating CF582.93M USD
CapEx (TTM)73.52M USD
FCF Margin20.78%
FCF Yield3.58%
Net Debt2.32B USD
Net Debt/EBITDA2.65
Balance Sheet
Debt/Equity0.47
Current Ratio1.80
Quick Ratio1.36
Book Value/Sh64.78 USD
Cash/Share9.17 USD
Dividends
Fwd Div Rate0.28 USD
Trail. Div Rate0.28 USD
Div. Yield0.18%
5Y Avg Yield0.23%
Payout Ratio13.40%
Ex-Div DateOct 23, 2026
Pay DateNov 13, 2026
Splits
Last Split2:1
Split DateJun 4, 2001
Analyst Consensus
Rating2.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)130.27 USD
Upside (mean)-14.0%
Target Range110.00 USD – 165.00 USD
110.00-14.0% to mean165.00
# Analysts15
Ownership
Shares Out.111.59M
Float102.49M
Insiders0.26%
Institutions96.55%
Short Interest
Short Ratio3.6d
Short % Float8.35%
Short % Out.5.57%
Shares Short6.22M
Short (prev mo.)6.42M
Technical
SMA 50127.82 (+18.5%)
SMA 200106.26 (+42.6%)
Beta1.09
S&P 52W Chg14.58%
Avg Vol (30d)2.06M
Avg Vol (10d)2.29M
Technical Indicators
RSI (14)69.2
MACD7.3918
MACD Signal7.1202
MACD Hist.+0.2715
BB Upper162.81 USD
BB Middle140.95 USD
BB Lower119.10 USD
BB Width31.01%
ATR (14)4.874 USD
Vol Ratio (20d)0.53x